Abstract
Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components involved in neurodegeneration to protect neurons from death. Cell cycle is a highly regulated process that controls the balance between proliferation, differentiation and death of every cell in the body. Aberrant expression and function of components of the cell cycle machinery have been linked to neurodegenerative diseases, in which different types of neuronal cells become dysfunctional and die in response to toxic insults. Since neurons are postmitotic cells, re-entry into the cell cycle has been shown to be pathological and contributes to the process of neurodegeneration. Moreover, an increasing number of studies highlight the importance of the role of cell cycle components outside the cell cycle and their involvement in neurodegenerative disorders. Here, we discuss the pleiotropic effects of PACAP on cell cycle machinery and the implication for the treatment of neurodegenerative diseases.
Keywords: Neurodegeneration, cell cycle re-entry, pituitary adenylyl cyclase activating polypeptide (PACAP), apoptosis, therapy, adult neurons.
Current Pharmaceutical Design
Title:Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases
Volume: 24 Issue: 33
Author(s): María José Polanco*Maria Pennuto*
Affiliation:
- Laboratory of Pharmacology and Toxicology, Department of Pharmaceutical and Health Sciences, Faculty of Pharmacy, San Pablo CEU University, Madrid,Spain
- Department of Biomedical Sciences, University of Padova, 35100 Padova,Italy
Keywords: Neurodegeneration, cell cycle re-entry, pituitary adenylyl cyclase activating polypeptide (PACAP), apoptosis, therapy, adult neurons.
Abstract: Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components involved in neurodegeneration to protect neurons from death. Cell cycle is a highly regulated process that controls the balance between proliferation, differentiation and death of every cell in the body. Aberrant expression and function of components of the cell cycle machinery have been linked to neurodegenerative diseases, in which different types of neuronal cells become dysfunctional and die in response to toxic insults. Since neurons are postmitotic cells, re-entry into the cell cycle has been shown to be pathological and contributes to the process of neurodegeneration. Moreover, an increasing number of studies highlight the importance of the role of cell cycle components outside the cell cycle and their involvement in neurodegenerative disorders. Here, we discuss the pleiotropic effects of PACAP on cell cycle machinery and the implication for the treatment of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Polanco José María *, Pennuto Maria*, Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases, Current Pharmaceutical Design 2018; 24 (33) . https://dx.doi.org/10.2174/1381612825666181127102311
DOI https://dx.doi.org/10.2174/1381612825666181127102311 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update
Current Genomics Current Research on Opioid Receptor Function
Current Drug Targets Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines
Current Drug Targets Berberine: A Fluorescent Alkaloid with a Variety of Applications from Medicine to Chemistry
Mini-Reviews in Organic Chemistry Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Impairment of Store-operated Calcium Entry: Implications in Alzheimer’s Neurodegeneration
Current Alzheimer Research Screening of Natural Compounds Against SOD1 as a Therapeutic Target for Amyotrophic Lateral Sclerosis
Letters in Drug Design & Discovery CDC25 Phosphatase Inhibitors: An Update
Mini-Reviews in Medicinal Chemistry Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Necroptosis: Who Knew There were so Many Interesting Ways to Die?
CNS & Neurological Disorders - Drug Targets Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Differences Between Parkinson’s and Huntington’s Diseases and Their Role for Prioritization of Stem Cell-Based Treatments
Current Molecular Medicine Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry